

## USPTO PATENT FULL-TEXT AND IMAGE DATABASE

<a href="#">Home</a>	<a href="#">Quick</a>	<a href="#">Advanced</a>	<a href="#">Pat Num</a>	<a href="#">Help</a>
<a href="#">Bottom</a>		<a href="#">View Cart</a>		

Searching US Patent Collection...

**Results of Search in US Patent Collection db for:**  
**(AN/JENAPHARM AND (estradiol AND valerate)):** 6 patents.  
*Hits 1 through 6 out of 6*

Jump To	<input type="text"/>
---------	----------------------

Refine Search	<input type="text" value="an/JENAPHARM and (estradiol and valerate)"/>
---------------	--

PAT. NO.	Title
1 <a href="#">6,902,741</a>	<a href="#">Laminates containing an active substance transdermal system</a>
2 <a href="#">6,884,793</a>	<a href="#">Combination preparation for contraception based on natural estrogens</a>
3 <a href="#">6,855,836</a>	<a href="#">17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds</a>
4 <a href="#">6,133,251</a>	<a href="#">Combination compound for contraception based on natural estrogen</a>
5 <a href="#">5,866,559</a>	<a href="#">17.alpha.-cyanomethylestra-4,9-dien derivatives and pharmaceutical compositions containing same</a>
6 <a href="#">5,855,905</a>	<a href="#">Compound preparation for the treatment of hypogonadal men and men with hypophyseal diseases</a>

---

<a href="#">Top</a>		<a href="#">View Cart</a>		
<a href="#">Home</a>	<a href="#">Quick</a>	<a href="#">Advanced</a>	<a href="#">Pat Num</a>	<a href="#">Help</a>

**USPTO PATENT FULL-TEXT AND IMAGE DATABASE**

<a href="#">Home</a>	<a href="#">Quick</a>	<a href="#">Advanced</a>	<a href="#">Pat Num</a>	<a href="#">Help</a>
<a href="#">Next List</a>		<a href="#">Bottom</a>	<a href="#">View Cart</a>	

Searching US Patent Collection...

**Results of Search in US Patent Collection db for:**

**(estradiol AND valerate): 734 patents.**

*Hits 1 through 50 out of 734*

[Next 50 Hits](#)

[Jump To](#)

[Refine Search](#)

PAT. NO.	Title
1 <a href="#">7,063,859</a>	<a href="#">Barrier film lined backing layer composition and method for topical administration of active agents</a>
2 <a href="#">7,056,909</a>	<a href="#">Alpha v integrin receptor antagonists</a>
3 <a href="#">7,056,591</a>	<a href="#">Hydrophobic biologically absorbable coatings for drug delivery devices and methods for fabricating the same</a>
4 <a href="#">7,053,077</a>	<a href="#">Use of biogenic estrogen sulfamates for hormone replacement therapy</a>
5 <a href="#">7,045,145</a>	<a href="#">Transdermal contraceptive delivery system and process</a>
6 <a href="#">7,038,085</a>	<a href="#">Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof</a>
7 <a href="#">7,030,104</a>	<a href="#">Topical oestroprogestational compositions with a systemic effect</a>
8 <a href="#">7,029,657</a>	<a href="#">Nasal spray steroid formulation and method</a>
9 <a href="#">7,026,447</a>	<a href="#">53 human secreted proteins</a>
10 <a href="#">7,026,360</a>	<a href="#">Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients</a>
11 <a href="#">7,022,334</a>	<a href="#">Therapeutic composition and a method of coating implantable medical devices</a>
12 <a href="#">7,015,248</a>	<a href="#">Use of abietic acid and derivatives thereof for inhibiting cancer</a>
13 <a href="#">7,014,913</a>	<a href="#">Rate-reducing membrane for release of an agent</a>
14 <a href="#">7,012,075</a>	<a href="#">Cathepsin cysteine protease inhibitors</a>
15 <a href="#">7,005,137</a>	<a href="#">Coating for implantable medical devices</a>
16 <a href="#">6,994,863</a>	<a href="#">Pharmaceutical and cosmetic carrier and composition for topical application</a>
17 <a href="#">6,994,857</a>	<a href="#">Albumin fusion proteins</a>
18 <a href="#">6,992,075</a>	<a href="#">C(14) estrogenic compounds</a>

- 19 [6,991,095](#) [T](#) [Packaging bag for plaster and packaged plaster](#)
- 20 [6,987,129](#) [T](#) [Compounds and methods for the treatment of urogenital disorders](#)
- 21 [6,987,101](#) [T](#) [Therapeutic gestagens for the treatment of premenstrual dysphoric disorder](#)
- 22 [6,979,347](#) [T](#) [Implantable drug delivery prosthesis](#)
- 23 [6,977,143](#) [T](#) [Determination of testosterone by mass spectrometry](#)
- 24 [6,974,802](#) [T](#) [Treatment of viral infections using prodrugs of 2',3'-dideoxy,3'-fluoroguanosine](#)
- 25 [6,967,023](#) [T](#) [Pharmaceutical and cosmetic carrier or composition for topical application](#)
- 26 [6,962,908](#) [T](#) [Oral pharmaceutical products containing 17 .beta.-estradiol-3-lower alkanoate, method of administering the same and process of preparation](#)
- 27 [6,960,337](#) [T](#) [Methods and compositions for treating benign gynecological disorders](#)
- 28 [6,958,327](#) [T](#) [18 Norsteroids as selectively active estrogens](#)
- 29 [6,958,326](#) [T](#) [Cyclodextrin-drospirenone inclusion complexes](#)
- 30 [6,958,154](#) [T](#) [Spray on bandage and drug delivery system](#)
- 31 [6,958,142](#) [T](#) [Nasal spray formulation and method](#)
- 32 [6,956,099](#) [T](#) [Polyamide-polyether block copolymer](#)
- 33 [6,951,942](#) [T](#) [Glucocorticoid-selective anti-inflammatory agents](#)
- 34 [6,951,924](#) [T](#) [Antibodies against secreted protein HTEBYII](#)
- 35 [6,946,134](#) [T](#) [Albumin fusion proteins](#)
- 36 [6,943,162](#) [T](#) [Piperazinyltriazines as estrogen receptor modulators](#)
- 37 [6,943,156](#) [T](#) [Dibenzoxazepine .alpha.v integrin receptor antagonist](#)
- 38 [6,936,268](#) [T](#) [Sheet-form adhesive preparation](#)
- 39 [6,932,777](#) [T](#) [Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer](#)
- 40 [6,929,803](#) [T](#) [Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings](#)
- 41 [6,926,898](#) [T](#) [Albumin fusion proteins](#)
- 42 [6,919,433](#) [T](#) [Antibodies to protein HPMBQ91](#)
- 43 [6,919,092](#) [T](#) [Method for the management of incontinence](#)
- 44 [6,916,810](#) [T](#) .alpha..nu. integrin receptor antagonists
- 45 [6,911,211](#) [T](#) [Pharmaceutical and cosmetic carrier or composition for topical application](#)
- 46 [6,906,049](#) [T](#) [Contraceptive medicine based on a progestational agent and an oestrogen and preparation method](#)
- 47 [6,905,688](#) [T](#) [Albumin fusion proteins](#)
- 48 [6,902,881](#) [T](#) [Compounds and methods for regulating cell differentiation](#)
- 49 [6,902,741](#) [T](#) [Laminates containing an active substance transdermal system](#)
- 50 [6,897,253](#) [T](#) [Stable aqueous surfactant compositions](#)
-

**USPTO PATENT FULL-TEXT AND IMAGE DATABASE**

<a href="#">Home</a>	<a href="#">Quick</a>	<a href="#">Advanced</a>	<a href="#">Pat Num</a>	<a href="#">Help</a>
<a href="#">Next List</a>	<a href="#">Bottom</a>	<a href="#">View Cart</a>		

Searching US Patent Collection...

**Results of Search in US Patent Collection db for:**

**ACLM/(estradiol AND valerate):** 84 patents.

*Hits 1 through 50 out of 84*

















Final 34 Hits

Jump To

Refine Search

aclm/(estradiol and valerate)

- | PAT.<br>NO.  | Title  |
|--------------|--|
| 1 7,030,104  | <a href="#">Topical oestroprogestational compositions with a systemic effect</a>   |
| 2 6,992,075  | <a href="#">C(14) estrogenic compounds</a>   |
| 3 6,987,101  | <a href="#">Therapeutic gestagens for the treatment of premenstrual dysphoric disorder</a>   |
| 4 6,958,326  | <a href="#">Cyclodextrin-drospirenone inclusion complexes</a>  |
| 5 6,884,793  | <a href="#">Combination preparation for contraception based on natural estrogens</a>   |
| 6 6,846,496  | <a href="#">Treatment of osteoporosis</a>  |
| 7 6,824,786  | <a href="#">Compositions comprising phenyl-glycine derivatives</a>   |
| 8 6,740,327  | <a href="#">Oligosaccharide aldonic acids and their topical use</a>  |
| 9 6,677,324  | <a href="#">Combination preparation of estrogen and anti-estrogen</a>  |
| 10 6,667,050 | <a href="#">Chewable oral contraceptive</a>  |
| 11 6,641,831 | <a href="#">Medical products with sustained pharmacological activity and process for producing them</a>  |
| 12 6,613,757 | <a href="#">COMBINATION OF PROSTACYCLIN WITH AN ESTROGEN OR PROGESTIN FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROTIC VASCULAR DISEASE INCLUDING PREECLAMPSIA AND FOR THE TREATMENT OF HYPERTENSION, AND FOR HORMONE REPLACEMENT THERAPY</a> |
| 13 6,585,997 | <a href="#">Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds</a>   |
| 14 6,497,897 | <a href="#">Plaster agent and method of preparing same</a>   |
| 15 6,335,023 | <a href="#">Oligosaccharide aldonic acids and their topical use</a>  |
| 16 6,329,354 | <a href="#">Methods for the treatment of osteoporosis</a>  |

- 17 [6,294,045](#)  [Plaster agent and method of preparing same](#)
- 18 [6,262,115](#)  [Method for the management of incontinence](#)
- 19 [6,242,509](#)  [Gels including bioactive components](#)
- 20 [6,165,491](#)  [Pharmaceutical composition based on estrogen and progesterone](#)
- 21 [6,156,341](#)  [Low-dosed steroid tablets that contain gallic acid ester as an antioxidant, process for production, and use](#)
- 22 [6,149,935](#)  [Solid matrix system for transdermal drug delivery](#)
- 23 [6,133,320](#)  [Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors](#)
- 24 [6,133,251](#)  [Combination compound for contraception based on natural estrogen](#)
- 25 [6,071,531](#)  [Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen](#)
- 26 [6,040,340](#)  [Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors](#)
- 27 [6,028,106](#)  [Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents](#)
- 28 [5,980,940](#)  [Pharmaceutical combination preparation for hormonal contraception](#)
- 29 [5,980,932](#)  [Solid matrix system for transdermal drug delivery](#)
- 30 [5,958,878](#)  [Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors](#)
- 31 [RE36,247](#)  [Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens](#)
- 32 [5,906,830](#)  [Supersaturated transdermal drug delivery systems, and methods for manufacturing the same](#)
- 33 [5,902,603](#)  [Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use](#)
- 34 [5,898,038](#)  [Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors](#)
- 35 [5,885,565](#)  [Methods for inducing phase separation of epithelial lipid bilayers](#)
- 36 [5,858,394](#)  [Agent for transdermal administration that contains gestodene esters](#)
- 37 [5,811,547](#)  [Method for inducing crystalline state transition in medicinal substance](#)
- 38 [5,789,442](#)  [Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents](#)
- 39 [5,770,219](#)  [Solid matrix system for transdermal drug delivery](#)
- 40 [5,756,490](#)  [Pharmaceutical combination preparation for hormonal contraception](#)
- 41 [5,723,114](#)  [Penetration enhancing compositions and methods of their use](#)
- 42 [5,719,197](#)  [Compositions and methods for topical administration of pharmaceutically active agents](#)
- 43 [5,708,038](#)  [Method of using aloe vera as a biological vehicle](#)
- 44 [5,660,839](#)  [Nongreasy/nonsticky fatty cosmetic/dermatological compositions](#)
- 45 [5,595,970](#)  [Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors](#)
- 46 [5,585,370](#)  [Hormone preparation and method](#)
- 47 [5,569,652](#)  [Dihydrospirorenone as an antiandrogen](#)
- 48 [5,554,601](#)  [Methods for neuroprotection](#)

- 49 [5,505,942](#) [Use of hydrolytic enzymes for the prophylaxis of spontaneous abortion in pregnant women with habitual idiopathic abortion in their anamneses](#)
- 50 [5,474,783](#) [Solubility parameter based drug delivery system and method for altering drug saturation concentration](#)
- 

<a href="#">Next List</a>	<a href="#">Top</a>	<a href="#">View Cart</a>		
<a href="#">Home</a>	<a href="#">Quick</a>	<a href="#">Advanced</a>	<a href="#">Pat Num</a>	<a href="#">Help</a>

## USPTO PATENT FULL-TEXT AND IMAGE DATABASE

<a href="#">Home</a>	<a href="#">Quick</a>	<a href="#">Advanced</a>	<a href="#">Pat Num</a>	<a href="#">Help</a>
<a href="#">Next List</a>		<a href="#">Bottom</a>	<a href="#">View Cart</a>	

Searching US Patent Collection...

**Results of Search in US Patent Collection db for:**  
**(ACLM/(estradiol AND valerate) AND estrogen): 65 patents.**  
*Hits 1 through 50 out of 65*

Final 15 Hits


























Jump To:

Refine Search

ac1m/(estradiol and valerate) and estrogen

- | PAT.<br>NO.  | Title  |
|--------------|--|
| 1 7,030,104  | <a href="#">T Topical oestroprogestational compositions with a systemic effect</a>   |
| 2 6,992,075  | <a href="#">T C(14) estrogenic compounds</a>   |
| 3 6,987,101  | <a href="#">T Therapeutic gestagens for the treatment of premenstrual dysphoric disorder</a>   |
| 4 6,958,326  | <a href="#">T Cyclodextrin-drospirenone inclusion complexes</a>  |
| 5 6,884,793  | <a href="#">T Combination preparation for contraception based on natural estrogens</a>   |
| 6 6,846,496  | <a href="#">T Treatment of osteoporosis</a>  |
| 7 6,677,324  | <a href="#">T Combination preparation of estrogen and anti-estrogen</a>  |
| 8 6,667,050  | <a href="#">T Chewable oral contraceptive</a>  |
| 9 6,641,831  | <a href="#">T Medical products with sustained pharmacological activity and process for producing them</a>  |
| 10 6,613,757 | <a href="#">T COMBINATION OF PROSTACYCLIN WITH AN ESTROGEN OR PROGESTIN FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROTIC VASCULAR DISEASE INCLUDING PREECLAMPSIA AND FOR THE TREATMENT OF HYPERTENSION, AND FOR HORMONE REPLACEMENT THERAPY</a> |
| 11 6,497,897 | <a href="#">T Plaster agent and method of preparing same</a>   |
| 12 6,329,354 | <a href="#">T Methods for the treatment of osteoporosis</a>  |
| 13 6,294,045 | <a href="#">T Plaster agent and method of preparing same</a>   |
| 14 6,262,115 | <a href="#">T Method for the management of incontinence</a>  |
| 15 6,165,491 | <a href="#">T Pharmaceutical composition based on estrogen and progesterone</a>  |
| 16 6,149,935 | <a href="#">T Solid matrix system for transdermal drug delivery</a>  |
| 17 6,133,320 | <a href="#">T Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate</a>   |


and/or donors

- 18 [6,133,251](#)  Combination compound for contraception based on natural estrogen
- 19 [6,071,531](#)  Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
- 20 [6,040,340](#)  Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
- 21 [6,028,106](#)  Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
- 22 [5,980,940](#)  Pharmaceutical combination preparation for hormonal contraception
- 23 [5,980,932](#)  Solid matrix system for transdermal drug delivery
- 24 [5,958,878](#)  Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors
- 25 [RE36,247](#)  Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
- 26 [5,902,603](#)  Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
- 27 [5,898,038](#)  Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
- 28 [5,858,394](#)  Agent for transdermal administration that contains gestodene esters
- 29 [5,811,547](#)  Method for inducing crystalline state transition in medicinal substance
- 30 [5,789,442](#)  Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
- 31 [5,770,219](#)  Solid matrix system for transdermal drug delivery
- 32 [5,756,490](#)  Pharmaceutical combination preparation for hormonal contraception
- 33 [5,719,197](#)  Compositions and methods for topical administration of pharmaceutically active agents
- 34 [5,708,038](#)  Method of using aloe vera as a biological vehicle
- 35 [5,595,970](#)  Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors
- 36 [5,585,370](#)  Hormone preparation and method
- 37 [5,569,652](#)  Dihydrospirorenone as an antiandrogen
- 38 [5,554,601](#)  Methods for neuroprotection
- 39 [5,505,942](#)  Use of hydrolytic enzymes for the prophylaxis of spontaneous abortion in pregnant women with habitual idiopathic abortion in their anamneses
- 40 [5,474,783](#)  Solubility parameter based drug delivery system and method for altering drug saturation concentration
- 41 [5,446,070](#)  Compositions and methods for topical administration of pharmaceutically active agents
- 42 [5,382,573](#)  Hormone preparation and method
- 43 [5,340,586](#)  Methods and formulations for use in treating oophorectomized women
- 44 [5,340,585](#)  Method and formulations for use in treating benign gynecological disorders
- 45 [5,340,584](#)  Methods and formulations for use in inhibiting conception and in treating benign gynecological disorders
- 46 [5,336,210](#)  Plaster agent
- 47 [5,211,952](#)  Contraceptive methods and formulations for use therein
- 48 [5,200,197](#)  Contraceptive pill





49 [5,116,865](#) [15,16-seco-19-nor progestins](#)

50 [5,098,714](#)  [Osmotic, oral dosage form for fertility control](#)

---

	<a href="#">Next List</a>	<a href="#">Top</a>	<a href="#">View Cart</a>	
<a href="#">Home</a>	<a href="#">Quick</a>	<a href="#">Advanced</a>	<a href="#">Pat Num</a>	<a href="#">Help</a>

[Sign in](#)[Web](#) [Images](#) [Groups](#) [News](#) [Froogle](#) [Maps](#) [more »](#)

estradiol and valerate

[Advanced Search](#)  
[Preferences](#)The "AND" operator is unnecessary -- we include all search terms by default. [\[details\]](#)**Web**Results 1 - 10 of about **143,000** for **estradiol and valerate**. (0.46 seconds)**ESTRADIOL VALERATE - INJECTION (Delestrogen) side effects, medical ...**Consumer information about the medication **ESTRADIOL VALERATE - INJECTION (Delestrogen)**, includes side effects, drug interactions, recommended dosages, ...[www.medicinenet.com/estradiol\\_valerate-injection/article.htm](http://www.medicinenet.com/estradiol_valerate-injection/article.htm) - 40k -[Cached](#) - [Similar pages](#)**Delestrogen****DELESTROGEN® (estradiol valerate injection, USP)** contains **estradiol valerate**, ... **Estradiol valerate** is designated chemically as estra-1,3,5(10)-triene-3, ...[www.rxlist.com/cgi/generic3/estradiolval.htm](http://www.rxlist.com/cgi/generic3/estradiolval.htm) - 24k -[Cached](#) - [Similar pages](#)**Delestrogen Indications, Dosage, Storage, Stability -****Estradiol ...****Estradiol valerate**. Delestrogen Online, Description, Chemistry, Ingredients - ... **DELESTROGEN (estradiol valerate injection, USP)** is indicated in the: ...[www.rxlist.com/cgi/generic3/estradiolval\\_ids.htm](http://www.rxlist.com/cgi/generic3/estradiolval_ids.htm) - 27k -[Cached](#) - [Similar pages](#)**Inhouse Pharmacy (UK) Estradiol valerate - Progynova - Ester 17b ...****Estradiol valerate** - Progynova - Ester 17b of **estradiol** with same effect as endogenous estrogen.[www.inhousepharmacy.co.uk/womens-hrt/progynova.html?](http://www.inhousepharmacy.co.uk/womens-hrt/progynova.html?PHPSESSID=73e599a1ca917a372a505244c5a73d54)[PHPSESSID=73e599a1ca917a372a505244c5a73d54](http://www.inhousepharmacy.co.uk/womens-hrt/progynova.html?PHPSESSID=73e599a1ca917a372a505244c5a73d54) - 32k - [Cached](#) - [Similar pages](#)**Inhouse Pharmacy (UK) Climen contains Cyproterone acetate and ...**10 pink tablets each containing **estradiol-17-valerate** 2 mg and cyproterone ... **Estradiol valerate** and cyproterone acetate are completely absorbed after oral ...[www.inhousepharmacy.co.uk/womens-hrt/climen-hrt.html?](http://www.inhousepharmacy.co.uk/womens-hrt/climen-hrt.html?PHPSESSID=f2cf44594b9974469e548b37d55ea0af)[PHPSESSID=f2cf44594b9974469e548b37d55ea0af](http://www.inhousepharmacy.co.uk/womens-hrt/climen-hrt.html?PHPSESSID=f2cf44594b9974469e548b37d55ea0af) - 39k - [Cached](#) - [Similar pages](#)**ESTRADIOL VALERATE Drug Information ESTRADIOL VALERATE****ESTRADIOL VALERATE** side effects, interactions, indications.[www.drugs.com/pdr/estradiol\\_valerate.html](http://www.drugs.com/pdr/estradiol_valerate.html) - 75k - [Cached](#) - [Similar pages](#)**The preclinical and clinical profile of Klimonorm®**The daily dose of 2 mg **estradiol valerate** (EV) assures sufficient estrogen replacement ...**Estradiol valerate** (EV) represents the natural estrogen **estradiol** ...[www.priory.com/focusestrad.htm](http://www.priory.com/focusestrad.htm) - 48k - [Cached](#) - [Similar pages](#)**A comparison of the pharmacokinetic properties of three estradiol ...**In order to assess the pharmacokinetics properties of **estradiol** cypionate, **valerate** and benzoate, the daily plasma levels of **estradiol** and estrone were ...[www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7389356&dopt=Abstract)[db=PubMed&list\\_uids=7389356&dopt=Abstract](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7389356&dopt=Abstract) - [Similar pages](#)**Sponsored Links****Estriol Cream at Amazon**

Low prices on estriol cream.

Qualified orders over \$25 ship free  
Amazon.com**Estriol Cream**

100,000 Stores. Deals. Reviews.

Estriol Cream &amp; More!

Yahoo.com

**Estradiol Valerate**

We have what you are looking for!

Find great offers for health aid.

[www.best-price.com/Health\\_Aids](http://www.best-price.com/Health_Aids)**Estriol Cream**

Here are the top 8

sites on Estriol Cream

[www.8bestsites.com](http://www.8bestsites.com)

**estradiol. Buy estradiol Online at Lowest Prices.**

... **estradiol estradiol high estradiol valerate estradiol and ivf estradiol order ... estradiol estradiol level buy estradiol valerate norethindrone acetate ...**  
freett.com/epills/estradiol.html - 13k - [Cached](#) - [Similar pages](#)

**CLIMEN TABLETS**

**Estradiol valerate** and cyproterone acetate are completely absorbed after oral administration. During the absorption process and the first liver passage, ...  
www.intekom.com/pharm/schering/climen.html - 12k - [Cached](#) - [Similar pages](#)

Try your search again on [Google Book Search](#)

Goooooooooooooogle ►  
Result Page:    1   2   3   4   5   6   7   8   9   10    **Next**

New! Get live World Cup scores on your computer  
[Download Google Desktop](#)

Google

ITLY vs US: Final Score

Italy	1
United States	1

Email

News

57°F Mostly Cloud

12:00 AM

[Search within results](#) | [Language Tools](#) | [Search Tips](#) | [Dissatisfied? Help us improve](#)

[Google Home](#) - [Advertising Programs](#) - [Business Solutions](#) - [About Google](#)

©2006 Google